Resolute to maintain its position as the world’s leading generics company, Teva has disclosed that its pipeline contains “more than 1,000 projects covering 80% of what’s going off-patent,” as it outlined a refocused five-year plan up to 2027 to return to growth both for revenues and earnings.
At the same time, for biosimilars the Israeli firm has the “same philosophy
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?